 AIM ImmunoTech Inc NYSEAMERICAN:AIM announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of its Ampligen drug as an intranasal therapy and reported no serious adverse events. The company said the positive safety data paves the way for an escalation of the dose in Cohort 2 and is a critical step in its ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for coronavirus COVID-19 and other respiratory viral diseases. 